Position in XERS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$558,018
+$23,567 QoQ
Shares Held
96,210
+41.3% QoQ
Ownership
0.056%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in XERS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026EntryPoint Capital, LLC holds $4,087,521 across 11 Drug Manufacturers - Specialty & Generic names. XERS ranks #3 (13.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
6,704 | $883,184 | |
| 2 | ZTS |
Zoetis Inc.
|
5,448 | $644,008 | |
| 3 | XERS |
Xeris Biopharma Holdings, Inc.
This page
|
96,210 | $558,018 | |
| 4 | PCRX |
Pacira BioSciences, Inc.
|
21,268 | $480,656 | |
| 5 | HLN |
Haleon plc
|
37,899 | $379,368 | |
| 6 | IRWD |
Ironwood Pharmaceuticals Inc
|
86,874 | $304,927 | |
| 7 | AKBA |
Akebia Therapeutics, Inc.
|
201,749 | $280,431 | |
| 8 | SIGA |
Siga Technologies Inc
|
38,200 | $204,370 |
All Filings in XERS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $558,018 | 96,210 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $534,451 | 68,083 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $431,542 | 53,015 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $340,438 | 72,899 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $415,625 | 75,706 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $178,856 | 52,760 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $98,704 | 34,633 | Shares | Sole | 2024-11-13 | |
| 2024-03-31 | $8,758 | 3,963 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||